DanCann Pharma A/S appoints Sarah Mai Lykke-Kjeldsen as new COO
COPENHAGEN, Denmark, 28 March 2022 – DanCann Pharma A/S (SS: DANCAN) (“DanCann Pharma” or the “Company”), hereby announce that the Company has appointed Sarah Mai Lykke-Kjeldsen as new Chief Operating Officer (“COO”).
DanCann Pharma A/S was formed in 2018 and has since then undergone an extensive development and maturation process. Following the establishment of the Biotech Pharm1 production facilities and last year's acquisition of the wholesale company CannGros ApS, the ambitious pharma company now focuses on strengthening the organization in order to ensure stable future operations.
Sarah Mai Lykke-Kjeldsen has an MSc in Business Administration from Syddansk Universitet in Kolding and has her strengths in areas such as change management, organizational development, and project management.
CEO, Jeppe Krog Rasmussen, comments:
“DanCann Pharma is a knowledge-intensive company with lots of dynamism going on. We are in the process of transforming ourselves from project to operation, and in this connection, Sarah will be an absolute key person with her structured approach taking this project into an actual operation by contributing and leading the Company management. Furthermore, the appointment of Sarah gives us an opportunity to streamline our organization and make an optimal distribution of tasks and functions in the Company. We look forward to a rewarding cross-organizational interaction in a coordinated organization, so that we can ensure stable operation and safe delivery of products to patients.”
The Company's top priority in the near future is to complete the work on the EU-GMP approval of DanCann Pharma's production facilities, just as the integration of the wholesale company CannGros, which became part of the DanCann Pharma Group in October last year.
Sarah Mai Lykke-Kjeldsen will join DanCann Pharma on 1 April 2022.
Disclaimer
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.
Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.
Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
About DanCann Pharma
DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution Company based in Denmark. The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.
DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen.
For more information, visit: www.dancann.com
For further information, please contact:
Jeppe Krog Rasmussen, CEO
E-mail: jkr@dancann.com
Website: www.dancann.com